Tempus reported a 36% year-over-year increase in Q1 revenue to $348.1 million and raised full-year guidance, citing acceleration in oncology testing and continued demand for its AI-enabled diagnostic platform. The company also reported a sixfold jump in minimal residual disease (MRD) testing volume to about 6,500 tests, along with hereditary testing growth. Tempus said R&D spending increased 34% year over year to $48.2 million and described operational momentum across its multimodal Lens platform. It also announced a multi-year collaboration with Merck for biomarker discovery and development using Tempus data and Lens analytics. In parallel, Tempus expanded an enterprise collaboration with Gilead to provide access to the Lens platform and datasets for oncology pipeline development. The company exited the quarter with $521.2 million in cash and cash equivalents. Investors are likely to track whether the raised guidance is sustained as MRD and hereditary testing volumes scale, and whether the Merck and Gilead agreements translate into additional model development and commercial utilization.